Kymera Therapeutics Inc

KYMR remains in a Stage 2 advancing uptrend with higher highs and lows intact. Price has pulled back into the rising 9/21 EMA zone and is holding above key support, offering a favorable entry. Although RSI and Options Score are overbought and a Bullish Exhaustion signal warns of potential pullback, the advancing regime, rising moving averages, and RS outperformance support a bullish bias. Execution on this pullback into dynamic EMA support is preferred, while monitoring for distribution risk at the June swing low.

• ↑97% stock gain over past year signals high momentum factor.
• ↑Phase 2b KT-621 enrollment completed early; topline data due by end-2026.
• ↓R&D spend of $98.2M in Q1 strains resources amid development risk.